Shorter Progression-Free Survival with Lapatinib in Breast Cancer

Share this content:
Lapatinib is associated with shorter progression-free survival, more toxicity in patients with HER2-positive breast cancer compared with trastuzumab.
Lapatinib is associated with shorter progression-free survival, more toxicity in patients with HER2-positive breast cancer compared with trastuzumab.

Lapatinib is associated with shorter progression-free survival (PFS) and more toxicity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer compared with trastuzumab, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

As part of the MA.31 trial which compared first-line anti-HER2 therapy for both of these treatment modalities, researchers led by Karen A. Gelmon, MD, FRCPC, of the British Columbia Cancer Agency studied 652 patients from July 2008 to December 2011. Primary endpoint was intent-to-treat PFS, and 537 had centrally confirmed HER2-positive tumors.

Dr. Gelmon and fellow authors found that median intent-to-treat PFS was 9 months with lapatinib and 11.3 with trastuzumab. In those with centrally confirmed HER2-positive tumors, median PFS was 9.1 months with lapatinib and 13.6 months with trastuzumab.

RELATED: Treating HER2-Positive Metastatic Breast Cancer with Combination Lapatinib, Trastuzumab

In addition, they found more instances of grade 3 or 4 diarrhea and rash in patients treated with lapatinib.

“As first-line therapy for HER2-positive metastatic breast cancer, lapatinib combined with taxane was associated with shorter PFS and more toxicity compared with trastuzumab combined with taxane,” they concluded.

Reference

  1. Gelmon, Karen A., et al. "Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31." Journal of Clinical Oncology. doi: 10.1200/JCO.2014.56.9590. [epub ahead of print]. March 16, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters